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Abstract
Background: The existence of a bi-directional relationship between tuberculosis (TB) and insulin resistance (IR)/
diabetes has been alluded to in literature. Although diabetes has been linked to increased tuberculosis risk, the
relationship between tuberculosis as a causative factor for IR remains unclear. The study aimed to determine if an
association existed between tuberculosis and IR development in adults with newly diagnosed pulmonary
tuberculosis at baseline. It was additionally aimed to document changes in IR status during TB follow-up periods.
Methods: This cross-sectional study evaluated ambulatory participants at baseline for IR prevalence via
anthropometry, biochemistry and diagnostic IR tests [homeostasis model assessment-IR (HOMA-IR) and quantitative
insulin sensitivity check index (QUICKI)]. A prospective cohort sub-section study was additionally performed on
approximately half of the baseline study population, who were followed-up at two and five months whilst on
tuberculosis treatment. Summary statistics, correlation co-efficients and appropriate analysis of variance were
used to describe and analyse data. Participants were excluded if they presented with other forms of tuberculosis,
were HIV-positive, obese or had any pre-disposing IR conditions such as diabetes or metabolic syndrome.
Results: Fifty-nine participants were included from August 2013 until December 2014 (33.95 ± 12.02 years old; 81.
4% male). IR prevalence was 25.4% at baseline, determined by a calculated HOMA-IR cut-off point of 2.477. Patients
with IR were younger (p = 0.04). Although the difference between IR levels in participants between baseline and
follow-up was not significant, a decrease was observed over time. The majority of participants (61.0%) presented
with a normal BMI at baseline. Mean baseline values of fasting glucose were within normal ranges (4.82 ± 0.
80 mmol/L), whereas increased mean CRP levels (60.18 ± 50.92 mg/L) and decreased mean HDL-cholesterol levels
(males: 0.94 ± 0.88 mmol/L; females: 1.14 ± 0.88 mmol/L) were found.
Conclusions: The study found an association between tuberculosis and IR development in newly diagnosed
pulmonary tuberculosis patients. Although not significant, IR levels decreased over time, which could be indicative
of a clinical improvement. A high prevalence of IR amongst young tuberculosis patients therefore highlights the
need for early identification in order to facilitate a reversal of IR and prevent possible IR-related complications.
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Background
The existence of a bi-directional relationship between
tuberculosis (TB) and insulin resistance (IR)/diabetes has
previously been alluded to in the literature. Although dia-
betes has been linked to an increased risk for TB develop-
ment, the role of TB as a causative factor for development
of IR remains unclear. Insulin resistance is often defined
as a condition where the body cells become resistant to
the effects of insulin [1–4], resulting in a larger than
normal insulin release to maintain a normal glycaemic
response in the body [5]. Insulin resistance has previ-
ously been postulated to have either a genetic or envir-
onmental causation [6] and has been implicated in the
aetiology of several diseases/conditions, such as the
metabolic syndrome, cardiovascular disease, polycystic
ovarian syndrome, hypertension, type 2 diabetes melli-
tus and obesity [6–9]. Although accurate diagnosis and
measurement of IR is currently challenging, the esti-
mated global prevalence ranges from 20 to 40% in the
general population [10, 11].
It has been hypothesised that stress resulting from a
long-term infection, such as TB or HIV, could increase
the occurrence of IR in the body [12–14]. Recent litera-
ture has also described occurrences of impaired glucose
tolerance, distortions in carbohydrate metabolism and
altered insulin action among newly diagnosed TB patients
[15–17]. The pro-inflammatory response accompanying a
period of infection is postulated to result in decreased in-
sulin production, which leads to a hyperglycaemic state
[12]. This process may also be accompanied by the release
of certain stress hormones such as epinephrine, cortisol
and glucagon, which further impair the action of insulin
[13]. The phenomenon of ‘transient hyperglycaemia’
(subsiding of glucose intolerance upon diagnosis after
active TB treatment) can also not be discounted [18, 19].
The effect of Rifampicin, one of the pharmaceutical agents
used in the treatment of TB, has also been found to result
in transient hyperglycaemia soon after treatment com-
mencement due to its strengthening of intestinal glucose
absorption [20]. Furthermore, according to Schwartz’s
theories, it has been postulated that the pancreas could be
assaulted by TB either via concomitant pancreatitis (result-
ing in heightened susceptibility to inflammation and/or
amyloidosis) or via the forced habitation of the pancreas
[21, 22]. Moreover, the persistence of TB bacteria in
adipose tissue has been thought to be a possible causative
factor for systemic IR [23].
To the author’s knowledge, there are no published stud-
ies documenting IR prevalence in pulmonary tuberculosis
(PTB) patients using HOMA-IR and QUICKI tests. Given
the high prevalence of both communicable and non-
communicable diseases in South Africa, it was considered
prudent to investigate the relationship between the two
morbidities in a developing country setting. The study
therefore aimed to determine if an association existed
between TB and IR development in ambulatory adults
with newly diagnosed PTB through the use of HOMA-IR
and QUICKI. It was additionally aimed to document
changes in IR status during follow-up. Once IR partici-
pants were identified, it was intended to document any
differences between the IR and non-IR groups.
Methods
Study population
A descriptive, cross-sectional study was undertaken and
participants were enrolled from the Albow Gardens clinic
in the Western sub-district of the Cape Metropole region
(South Africa) from August 2013 until December 2014.
Recruitment was done via non-random, purposive sam-
pling and participants were included in the study if they
were newly diagnosed with PTB (either via molecular,
microbiological or radiographical testing), were between
the ages of 18–65 years old, on a standardised TB treat-
ment regime, HIV-negative and willing to provide a blood
sample. Participants were excluded if they presented with
any other forms of tuberculosis, were HIV-positive, had
increased anthropometrical values [obese (BMI ≥30 kg/
m2) or increased waist circumference measurement (males
>102 cm; females >88 cm)] or had any pre-disposing IR
conditions (such as diabetes or metabolic syndrome).
Once participants had been identified for participation in
the cross-sectional study, approximately half (n = 29) were
selected to be followed up at two and five months after
tuberculosis treatment commencement by means of a
prospective cohort sub-section study.
The study was approved by the Health Research Ethics
Committee of the Faculty of Medicine and Health
Sciences, Stellenbosch University in October 2012 (S12/
08/227). Permission was also granted (April 2013) by the
City of Cape Town (CoCT) to recruit participants from
the Albow Gardens clinic (ref number:10346). Participants
were required to give written informed consent prior to
data collection. Privacy of participants for the duration of
the study was ensured by making use of an anonymous
approach.
Anthropometry
The weight (calibrated, beam-balance scale) and height
(fixed stadiometer) of each participant was measured at
baseline according to standardised techniques [24]. The
Body Mass Index (BMI) of each participant was subse-
quently calculated and classified according to the for-
mula: Weight (kg)/height (m)2 [25]. The waist and hip
circumferences were measured using a non-stretchable
tape measure and were also performed using standar-
dised techniques [24]. The waist: hip ratio was calcu-
lated using the formula: waist circumference (cm)/hip
circumference (cm) and classified according to the
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World Health Organisation (WHO) cut-off points [26].
Four skinfold measurements were taken, namely biceps,
triceps, subscapular and suprailieac, according to stan-
dardised techniques for these measurements. A reliable
skinfold calliper (Harpenden) was used to perform all
measurements. Fat mass, fat free mass and body fat
percentage were then calculated based on the sum of
skinfold measurements and classified accordingly. The
average of three measurements was taken for weight,
height, waist and hip circumferences, as well as skinfold
measurements. Only the height was measured at base-
line, whilst all remaining anthropometrical measure-
ments were performed at all follow-up visits.
Biochemistry
A maximum of 15 ml of blood was collected from each
participant, after a 10-h overnight fast. Samples were
taken by a trained nursing sister at the data collection site
and transported under correct storage conditions to the
laboratory of the National Health Laboratory Services
(NHLS). Albumin (bromocresol green solution), fasting
glucose, C-reactive protein (CRP) and lipid profile were
analysed using the Siemens Advia 1800. With regard to
the lipid profile, total cholesterol was analysed using an
enzymatic method, whilst the triglyceride value was calcu-
lated using the Fossati three-step enzymatic reaction.
LDL-cholesterol was determined by means of the Friede-
wald formula [27]. The white cell count was performed by
the Siemens Advia 2120 whilst fasting insulin was
analysed with the help of ADVIA Centaur® Insulin Lite
Reagent and Solid Phase. Standardised reference ranges of
the NHLS were used to classify biochemical values.
Diagnostic IR-tests
The HOMA-IR diagnostic test was performed according
to the following formula: [Fasting serum insulin (μU/ml) x
fasting plasma glucose (mmol/L)]/22.5 [28]. The QUICKI
measurement is the inverse logarithm of the HOMA-IR
calculation, namely: 1/ [log (fasting insulin μU/ml) + log
(fasting glucose mg/dL] [29]. As there is currently no stan-
dardised cut-off point for either the HOMA-IR or the
QUICKI measurement, the data generated by this study
was used to calculate a relevant HOMA-IR cut-off point.
This was based on the lower limit of the upper quartile
(P75), as has been performed in similar studies [30–33].
Once the HOMA-IR cut-off had been calculated, the cor-
responding QUICKI value was determined by means of a
receiver operating characteristic (ROC) curve analysis.
Any individual having a HOMA-IR value greater than the
calculated cut-off point, as well as below the QUICKI cut-
off point, was classified as having possible IR. The
HOMA-IR was used as the primary tool for identifying IR
and the QUICKI was calculated to reinforce or compare
results.
Statistical analysis
Statistical analysis was performed using STATISTICA
version 12 [StatSoft Inc. (2014)] and Microsoft Excel 2010.
Summary statistics were used to describe data. Results
were expressed as mean ± standard deviation. Regression
and correlation analysis were utilised to document the
relationship between continuous variables. Appropriate
analysis of variance was used to investigate relations be-
tween continuous variables and nominal variables, whilst
Bootstrap procedures were used in cases where the resid-
uals were not normally distributed. For variables mea-
sured repeatedly over time, repeated measures ANOVA
were done with the compound symmetry assumption on
the correlation structure over time. ROC curves were per-
formed to calculate the corresponding QUICKI cut-off
point at baseline. A p-value of p < 0.05 represented statis-
tical significance in hypothesis testing and 95% confidence
intervals were used to describe the estimation of unknown
parameters. The power analysis was done to estimate the
sample size of participants needed at baseline (n = 30) and
those seen at two and five months (n = 29). A power of
90% was able to detect a medium effect size of 0.6.
Results
Fifty-nine participants were recruited during the 17 month
data collection period. A flow diagram indicating the
inclusion of study participants is shown in Fig. 1. The
majority of patients were male (81.4%) and had a mean
age of 33.95 ± 12.02 years.
Anthropometry
The majority of participants (n = 36, 61.0%) had a base-
line BMI in the normal range according to WHO cut-off
points (18.50–24.99 kg/m2) [25], while 33.9% (n = 20)
had a BMI of <18.5 kg/m2, classifying them with varying
levels of underweight. All of the anthropometrical mea-
surements experienced a significant increase over time
(p < 0.05), except for the biceps skinfold (Table 1). These
increases occurred mainly in the first two months after
treatment commencement.
Biochemistry
Baseline biochemistry results showed that the majority
of patients (n = 50; 84.7%) had an increased mean CRP
level (60.18 ± 50.92 mg/L) and decreased mean HDL-
cholesterol level (n = 41; 69.5%) at baseline (males:
0.94 ± 0.88 mmol/L; females: 1.14 ± 0.88 mmol/L).
Mean fasting glucose (4.82 ± 0.80 mmol/L), fasting in-
sulin (11.37 ± 19.20 mU/L), albumin (39.32 ± 4.35 g/L)
and white cell count (8.84 ± 3.56 10ˆ9/L) were all in
the normal reference ranges. According to fasting glu-
cose levels at baseline, 1.7% (n = 1) and 3.4% (n = 2) of
participants could be classified as having impaired
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fasting glucose (IFG) (6.1 mmol/L – 6.9 mmol/L) and
diabetes (≥7 mmol/L) respectively [34].
Significant changes over time were seen with a decrease
in both CRP (<0.001) and white cell count levels (<0.001),
while albumin experienced an increase (<0.001). Total,
LDL and HDL-cholesterol experienced a significant in-
crease in the first two months of treatment, followed by a
tapering off between two and five months (Table 1).
Insulin resistance
The 75th percentile of the HOMA-IR was calculated using
data collected from participants (cut-off value of 2.477). A
corresponding QUICKI cut-off point was calculated on the
basis of the HOMA-IR and a value of 0.336 was obtained.
Using this information, 25.4% (n = 15) participants were
classified with IR at baseline (Fig. 2). Participants with post-
recruitment possible metabolic syndrome [according to
Fig. 1 Flow diagram for inclusion of study participants. Group 1 = Participants seen at baseline only; Group 2 = Participants seen at baseline, two and
five months; TB = tuberculosis; PTB = pulmonary tuberculosis; HIV = human immunodeficiency virus; BMI = Body Mass Index; DM = diabetes mellitus
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International Diabetes Federation (IDF) (n = 2) [2, 35] and
Adult Treatment Panel III (ATP III) (n = 1) [36] criteria]
and diabetes (n = 2) were excluded in further sub-
analyses, which resulted in a minimal difference in overall
prevalence rates of IR (IDF: 24.6%; ATP III: 25.9%; pos-
sible diabetes: 24.6%).
Regression analysis showed the anthropometrical mea-
surements of waist circumference (r = 0.507; p = 0.011),
sum of skinfolds (r = 0.353; p = 0.039) and fat mass
(r = −2.419; p = 0.08) were the best predictors of IR at
baseline. Although the difference experienced between
HOMA-IR levels in participants between baseline and
follow-up periods was not significant (p = 0.311), a de-
crease was experienced over time (Fig. 3). Participants in
the follow-up group (n = 29), showed a 31% prevalence
of IR at baseline (n = 9), compared to 27.6% (n = 8) and
20.7% (n = 6) at two and five months respectively.
Insulin resistant vs. non-insulin resistant groups
Patients with IR were shown to be younger (p = 0.04)
(Fig. 4) and had a higher fasting insulin measurement












Weight kg F(2,56) = 39.51 56.83 (10.66) 59.76 (11.65) 61.37 (11.26) <0.001
BMI kg/m2 F(2,56) = 39.34 19.65 (2.62) 20.66 (2.93) 21.21 (2.68) <0.001
Waist circumference cm F(2,56) = 38.44 70.38 (8.84) 72.95 (9.32) 75.40 (9.18) <0.001
Waist:hip ratio - F(2,56) = 36.29 0.83 (0.08) 0.85 (0.09) 0.88 (0.09) <0.001
Biceps skinfold mm F(2,56) = 1.81 3.16 (1.45) 3.36 (1.96) 3.49 (2.02) 0.174
Triceps skinfold mm F(2,56) = 10.05 7.01 (4.05) 7.49 (4.29) 8.13 (4.63) <0.001
Subscapular skinfold mm F(2,56) = 10.22 7.77 (2.85) 8.26 (2.69) 8.79 (3.35) <0.001
Suprailiac skinfold mm F(2,56) = 6.81 6.10 (4.61) 7.32 (5.50) 7.57 (5.11) 0.002
Sum of skinfolds mm F(2,56) = 8.64 24.03 (11.79) 26.43 (13.47) 27.99 (14.18) <0.001
Fat mass kg F(2,56) = 17.63 7.22 (4.34) 8.38 (4.39) 8.73 (4.50) <0.001
Fat free mass kg F(2,56) = 38.11 49.61 (9.56) 51.38 (10.13) 52.63 (10.23) <0.001
Percentage body fat % F(2,56) = 10.89 12.58 (6.53) 13.85 (5.96) 14.19 (6.31) <0.001
Biochemistry
Albumin g/L F(2,56) = 15.36 39.97 (4.06) 42.55 (3.90) 43.41 (3.77) <0.001
Fasting glucose mmol/L F(2,56) = 2.11 4.78 (0.61) 4.83 (0.58) 4.57 (0.50) 0.131
CRP mmol/L F(2,56) = 21.63 56.72 (50.83) 27.54 (32.11) 12.48 (15.07) <0.001
Fasting insulin mU/l F(2,56) = 1.16 14.62 (25.98) 11.91 (15.81) 8.99 (6.77) 0.320
Total cholesterol mg/L F(2,56) = 10.43 3.55 (0.95) 4.20 (1.06) 3.94 (0.84) <0.001
Triglycerides mmol/L F(2,56) = 0.85 0.85 (0.30) 0.93 (0.38) 0.89 (0.38) 0.432
HDL-cholesterol mmol/L F(2,56) = 14.50 0.99 (0.30) 1.30 (0.46) 1.31 (0.38) <0.001
LDL-cholesterol mmol/L F(2,56) = 4.97 2.17 (0.75) 2.48 (0.87) 2.22 (0.70) 0.010
White cell count 10ˆ9/L F(2,56) = 16.30 8.74 (4.18) 6.98 (2.91) 5.92 (2.01) <0.001
SD = standard deviation, BMI = Body Mass Index, CRP = C-reactive protein, HDL = high density lipoprotein, LDL = low density lipoprotein
Bold variables indicate statistical significance
Fig. 2 Classification of total population at baseline according to
determined HOMA-IR cut-off point (n = 59). IR = insulin resistance;
HOMA-IR = homeostasis model assessment-insulin resistance
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(p < 0.01). Despite no significance between the groups in
terms of CRP levels, the IR group had a lower mean
value (p = 0.51). There were also no significant differ-
ences between gender, age groups, race, BMI classifica-
tion or waist circumference classification between IR
and non-IR groups at baseline (Table 2). Upon consider-
ation of differences between IR and non-IR groups at
the two and five month follow-up visits, there were no
significant results for any of the variables.
Discussion
Despite the mean BMI at baseline being classified in
the normal range for both males and females, there was
an overall prevalence of 33.9% of undernutrition (BMI
<18.5 kg/m2) among the study population. These rates
of undernutrition are in agreement with previously de-
scribed rates of between 20% and 71.6% [37].
A low BMI at diagnosis has been linked to an in-
creased risk of relapse [38] and demonstrates an indirectly
Fig. 3 Changes in HOMA-IR values of participants over five-month follow-up period (n = 29). HOMA-IR = homeostasis model
assessment-insulin resistance
Fig. 4 Comparison between the IR and non-IR group vs. age of participants (n = 59). IR: insulin resistance. p = 0.04*. Mean (years) ± SD: non-IR-
group (35.43 ± 12.02); IR group (29.60 ± 11.29)
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proportional relationship existing between BMI and mor-
tality risk [39]. Previous studies have also indicated that
the occurrence of undernutrition among TB patients
cannot be solely attributed to the disease itself but rather
to a multitude of contributing factors, such as extreme
poverty, food insecurity and reduced health-seeking be-
haviour [40, 41].
The majority of anthropometrical measurements showed
a significant increase whilst the patients were on treat-
ment, with the greatest changes taking place during
the intensive phase (first two months of treatment)
[42]. However, some patients failed to gain more than
5% weight over the five-month period and/or
remained in the underweight BMI category, thereby
placing them at greater risk of treatment failure and/
or relapse at a later stage [38]. Overall weight gain of
TB patients whilst on treatment is a common
phenomenon [43–47] although some researchers are
hesitant to use weight gain as a marker of successful
response to treatment [48, 49].
Findings verifying low levels of albumin and high
CRP levels in TB patients have been well documented
in literature [50–54]. Baseline study results yielded an
elevated mean CRP, while the mean albumin level was
in the normal range. It is perhaps the raised CRP level
that is more indicative of active TB disease because it
has been described as a non-specific measure of sys-
temic inflammation in the body [51]. The degree of
CRP escalation has also been linked to the presence of
weight loss and to disease severity, and this may in-
crease levels even further [51]. The albumin levels were
possibly not as severely affected due to the patients
being relatively ‘well’ TB patients (i.e. with predomin-
antly normal BMI’s, not hospitalised, drug-resistant or
HIV-co-infected).
A lowered total cholesterol level has previously been
described in the literature [51, 55, 56], in which it was
hypothesised that prolonged persistence of the TB
bacterium may result in cholesterol breakdown, especially
in persons who had been infected latently for a period of
Table 2 Comparison of baseline variables of IR group vs. non-IR group (continuous and categorical variables) (n = 59)
Variable (Baseline) Unit Non-IR Group (n = 44)
Mean (SD)




Age years 35.43 (12.02) 29.60 (11.29) 0.04
Systolic blood pressure mmHg 119.23 (17.78) 125.13 (11.57) 0.13
Diastolic blood pressure mmHg 75.45 (12.46) 79.93 (10.42) 0.05
Albumin g/L 38.75 (4.58) 41.00 (3.16) 0.17
Fasting glucose mmol/L 4.71 (0.69) 5.13 (1.02) 0.16
CRP mmol/L 64.10 (53.82) 48.91 (41.01) 0.51
Fasting insulin mU/l 5.63 (2.43) 28.20 (33.21) <0.01
Total cholesterol mg/L 3.39 (0.87) 3.71 (0.95) 0.30
Triglycerides mmol/L 0.88 (0.35) 0.95 (0.27) 0.38
HDL-cholesterol mmol/L 0.99 (0.33) 0.93 (0.26) 0.56
LDL-cholesterol mmol/L 1.98 (0.65) 2.35 (0.80) 0.24
White cell count 10ˆ9/l 8.79 (3.68) 8.99 (3.30) 0.68
HOMA-IR - 1.18 (0.54) 7.22 (10.32) <0.01
QUICKI - 0.39 (0.04) 0.31 (0.03) <0.01
Categorical variables
Groups assessed p-value***
Gender IR vs. non-IR 0.877
Age groups** IR vs. non-IR 0.210
Race IR vs. non-IR 0.816
BMI classification IR vs. non-IR 0.217
Waist circumference classification IR vs. non-IR 0.122
SD = standard deviation, CRP = C-reactive protein, HDL = high density lipoprotein, LDL = low density lipoprotein, HOMA-IR = homeostasis model assessment-
insulin resistance, QUICKI = quantitative insulin sensitivity check index
Bold and shaded variables indicate statistical significance
*Mann-Whitney U test
**Age groups concerned: 18–30 years; 31–45 years; 46–65 years
*** cc Maximum-likelihood chi square test
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time. Reduced HDL levels have been reported in numer-
ous studies with various infectious or inflammatory condi-
tions [57–59]. A study by Deniz et al. in 2007 showed
lowered levels of HDL-cholesterol in their PTB-specific
study population [56], which could be linked to the acti-
vated acute phase response (APR) often seen in TB disease
[60–63].
The current study saw an increase in albumin levels, as
well as a decrease in CRP (both over time). This would
suggest a ‘resolution’ of the APR or a suppression of the
inflammatory response [52], which is a phenomenon well
reported in literature, both for albumin [64] and CRP
[52–54, 64, 65]. There were, however, some patients in the
follow-up group who still presented with a raised CRP at
the five-month mark, which could perhaps indicate a sub-
optimal treatment response [53] or the presence of other
infections, especially if the CRP did not show an overall
downward trend. Total cholesterol, as well as LDL-and
HDL-cholesterol, experienced a significant increase during
the intensive treatment phase. There were however no
significant differences between the two-and five-month
periods. This is an unusual finding because one might
expect the values to increase even more at the end of the
follow-up period and warrants more investigation given
the important role of adequate cholesterol levels in pro-
tection against the mycobacteria.
One individual in the current study was classified
with IFG (1.7%) and two with diabetes (3.4%). A sys-
tematic review published by Jeon et al. in 2010 showed
total DM prevalence in TB patients to fall between the
range of 1.9% and 35% [66], but some of these were
diagnosed only after development of TB. The two ‘sus-
pected’ diabetic patients were, however, not confirmed
as having diabetes. In a cross-sectional study conducted
in West Africa, participants displayed a 5% IFG and a
1.9% DM rate, which is comparable with the current
study despite differing inclusion criteria [67]. A retro-
spective study performed in Sri Lanka found 7.1% pre-
existing DM among their study sample, as well as 20%
IFG and 2% DM rates (although lower fasting glucose
cut-off values were used) [68]. These raised levels could
also be attributed to the “stress/transient hypergly-
caemia” phenomenon [18, 19, 69, 70], as well as the
pro-inflammatory response [12, 13] and medication ef-
fects [20].
The HOMA-IR is one of the so-called ‘fasting indices’,
which utilises fasting measurements of both glucose and
insulin. The HOMA-IR has been used extensively in epi-
demiological research and as a routine measurement in
clinical practice [71] and together with the QUICKI [29]
has proved to be a very popular fasting index [28]. Al-
though the current gold-standard method of diagnosing
IR, the hyperinsulinaemic-euglycemic clamp (HEC), is
very often the preferred diagnostic tool, the inherent study
design did not lend itself to this particular technique,
largely due to the time-consuming nature of the test and
the fact that study participants were ambulatory out-
patients. A notable drawback of the HOMA-IR and
QUICKI is, however, the lack of a standardised cut-off
point to identify individuals with IR. Previous studies have
suggested that IR occurs between the HOMA-IR levels of
2.1 and 3.8 [28, 72], which is a vast range but in which the
value of 2.477 calculated in this study fits comfortably.
Using this calculated cut-off point, the IR prevalence at
baseline among this study population was 25.4%, which
equates to one in four persons with newly diagnosed PTB
having IR. These findings were echoed by the QUICKI.
This prevalence rate falls within the proposed range of
20–40% IR in the general population, of whom the major-
ity are healthy persons (i.e. do not have TB) [11, 71].
Recent studies have duly reported high levels of hypergly-
caemia, impaired glucose tolerance and DM in TB pa-
tients [12, 15–19, 66, 69, 70, 73–78].
The follow-up profiles of both HOMA-IR and QUICKI
seemed to indicate an improvement in IR over time.
Although there were no significant differences noted
between any of the time frames, there was an overall
downward pattern with the HOMA-IR and an upward
curve for the QUICKI, both signifying a ‘lessening’ of the
IR state. This ties in closely with an improved and dimin-
ishing inflammatory response, as demonstrated with the
improved CRP, albumin and white cell count. This could
also be due to the well-described ‘stress or transient’
hyperglycaemia seen to occur in the early stages after TB
diagnosis and which often resolves with progression of
treatment [18, 19, 73]. Despite the largely improved IR
status over the five-month follow-up period, two partici-
pants who had normal HOMA-IR and QUICKI values at
baseline subsequently developed IR at two and five
months, and two patients redeveloped IR at five months
after originally presenting with it at baseline. This contests
the stress hyperglyacemia hypothesis, as well as the im-
provement of an inflammatory state, and is an interesting
phenomenon to be pursued.
The development of IR has often been linked to the
process of aging [29, 79], since age progression is generally
associated with greater gains in body weight and/or fat
mass, especially in the central area of the body [80], as
well as with an increased prevalence of chronic diseases of
the lifestyle, including metabolic syndrome [81, 82]. As
the younger patients in this study displayed a greater
prevalence of IR, this could signal the need for increased
awareness of greater disease potential among the more
youthful TB population, despite contrasting results to
date. Recent research has indicated the possibility of
genetic influences on the development of IR, although at
the present moment, minimal variants have been associ-
ated herewith [83].
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There is generally a greater risk of IR with increasing
anthropometrical measurements [84], and positive cor-
relations have been documented between IR and BMI
[85, 86], waist and hip circumference, body fat content
and weight gain [87, 88]. Several of these were seen in
the current study (i.e. percentage body fat) and could
perhaps be indicative of the phenomenon of increasing
anthropometric measurements. A study conducted in
2012 by Addo et al. among adolescents in the United
States showed that skinfolds (tricep and subscapular)
were able to identify individuals at risk of developing IR
[89]. The sum of skinfolds could perhaps be used as a
marker to identify those at risk of developing IR, which
may be prudent in populations that do not exhibit typ-
ical metabolic syndrome-like characteristics.
Because IR is largely termed an ‘inflammatory’ condi-
tion, levels of CRP (a positive acute phase protein) are
often raised [90]. The inflammation typically found in
IR is more of a ‘low-grade’ inflammatory state, which is
often the result of the production of cytokines from vis-
ceral adipose tissue (VAT) [91]. The CRP levels are
often produced as a response to the release of various
cytokines designed to enable the inflammatory response
[92]. One might thus have expected the CRP levels of
the IR participants to be higher than the non-IR group,
given the inflammatory nature of IR itself, its relation-
ship with the APR and the fact that TB patients gener-
ally have increased CRP levels. However, the converse
was seen. Given the fact that patients included in this
study did not fit the conventional ‘metabolic syndrome’
or obesity profile, it could be speculated that they may
have slightly higher levels of subcutaneous fat, compared
with visceral tissue, which would, therefore, render a
slightly less inflammatory profile, and this could have an
inhibitory effect on CRP levels in the blood.
Leptin, an adipokine, has recently come under scru-
tiny regarding its role as a regulator of the immune
system, as well as its effect on appetite [93] and IR
reduction [94]. Findings regarding leptin levels in TB
have to date been conflicting, with some studies show-
ing higher leptin levels in TB patients [95–97] and
others showing lower levels [98–101]. Individuals with
reduced leptin concentrations have experienced an in-
creased body weight over a short time duration, [102]
which may be prudent in further investigating the link
between TB and IR.
Recommendations for clinical practice include the
implementation of integrative bi-directional screening
(TB and DM) in health care facilities, as well as close
monitoring of TB patients presenting with hypergly-
caemia upon treatment commencement. Vulnerable pa-
tients with an undesirable anthropometrical, biochemical
or clinical presentation should also be referred timeously
for nutritional support, preferably during the intensive
phase of treatment. Regarding future research avenues, it
would be prudent to assess IR prevalence in other suscep-
tible TB populations (HIV-co-infected, extra-pulmonary
patients and different life stages) as well as to utilise
additional IR diagnostic tools. Re-assessment of patients
who developed IR at the five-month mark may also yield
valuable results once treatment is completed. Although it
was not possible in this study, a desired outcome could be
the determination of a specific biomarker cut-off (e.g.
CRP) that would be able to identify IR in TB patients and
largely act as a diagnostic tool.
Limitations of the study included the paucity of standar-
dised reference values for HOMA-IR and QUICKI, as well
as issues surrounding the reliability of the fasting insulin
measurement. It was furthermore unclear whether patients
presented with hyperglycaemia before study recruitment.
Logistical issues such as the stipulated time of data collec-
tion (as IR is reportedly higher in the morning), patients
already having commenced with TB treatment, use of a
single recruitment site, compliance with overnight fasting
guidelines and inherent aspects of the study design (includ-
ing sample size) could also be viewed as limitations.
Conclusion
This study found an association between TB and IR
development in newly diagnosed PTB patients, with one
in four patients having IR. This high prevalence rate in
the study population signals the need for early identifica-
tion, especially in the younger and more vulnerable TB
population, in order to facilitate a possible reversal of IR
and prevent future IR-related complications.
Abbreviations
APR: Acute phase response; ATP III: Adult Treatment Panel III; BMI: Body Mass
Index; CoCT: City of Cape Town; CRP: C-reactive protein; DM: Diabetes
mellitus; HDL: High density lipoprotein; HEC: Hyperinsulinaemic-euglycemic
clamp; HIV: Human immunodeficiency virus; HOMA-IR: Homeostasis model
assessment-insulin resistance; IDF: International Diabetes Federation;
IFG: Impaired fasting; IR: Insulin resistance; LDL: Low density lipoprotein;
NHLS: National Health Laboratory Services; PTB: Pulmonary tuberculosis;
QUICKI: Quantitative insulin sensitivity check index; ROC: Receiver operating
characteristic; SD: Standard deviation; TB: Tuberculosis; VAT: Visceral adipose
tissue; WHO: World Health Organisation
Acknowledgements
The authors would like to acknowledge the South African Medical Research
Council (SAMRC) as a funding source for this project. Gratitude is also extended
to Professor Peter Donald and Dr. Florian Von Groote-Bidlingmaier for their in-
put from the conceptual stages of the project, as well as the management and
staff of the TASK team at Brooklyn Chest Hospital and Albow Gardens Clinic.
Funding
LP was funded by the National Health Scholars Programme (NHSP) of the SAMRC.
Additional funding was secured from the Harry Crossley Foundation and National
Research Foundation (NRF). Funding from the SAMRC was purely for scholarship
purposes, and other funding served to conduct the study (data collection costs).
None of the above funding bodies participated in study design, data collection,
analysis or interpretation of results, or manuscript preparation.
Philips et al. BMC Infectious Diseases  (2017) 17:570 Page 9 of 12
Availability of data and materials
Please note that due to Stellenbosch University embargo’s on raw data, this
will not be deposited publicly. Interested individuals/parties are welcome to
contact the author for more information concerning the raw data should
any queries arise.
Authors’ contributions
LP designed the study, collected and interpreted the data, drafted the
manuscript. JV and RB assisted with study design and interpretation of
data, revised the manuscript. DN analysed and interpreted the data,
revised the manuscript. All authors read and approved the final
manuscript.
Ethics approval and consent to participate
Mentioned under “Methods – Study population” in text.
[Health Research Ethics Committee of the Faculty of Medicine and Health




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Human Nutrition, Faculty of Medicine and Health Sciences,
Stellenbosch University, Cape Town, South Africa. 2Centre for Statistical
Consultation, Stellenbosch University, Cape Town, South Africa.
Received: 29 November 2016 Accepted: 1 August 2017
References
1. Mao F, Chen T, Zhao Y, et al. Insulin resistance: a potential marker and risk
factor for active tuberculosis? Med Hypotheses. 2011;77(1):66–8.
2. International Diabetes Federation. The IDF consensus worldwide definition
of the Metabolic Syndrome ([article online].2006. https://www.idf.org/our-
activities/advocacy-awareness/resources-and-tools/60:idfconsensus-
worldwide-definitionof-the-metabolic-syndrome.html. Accessed 10 Aug
2017.
3. Trout K, Homko C, Tkacs NC. Methods of measuring insulin sensitivity. Biol
Res Nurs. 2007;8(4):305–18.
4. Cefalu WT, Leahy JL, Clark NG. Medical management of diabetes mellitus.
New York; 2000. p. 57–75.
5. Mlinar B, Marc J, Janez A, Pfeifer M. Molecular mechanisms of insulin
resistance and associated diseases. Clin Chim Acta. 2007;375(1–2):20–35.
6. Granberry MC, Fonseca VA. Insulin resistance syndrome: options for
treatment. South Med J. 1999;92(1):2–15.
7. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;
37(12):1595–607.
8. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest.
2000;106(4):453–8.
9. Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic
syndrome. Endocrinol Metab Clin N Am. 2004;33(2):417–29.
10. Matsuda M, DeFronzo RA. Insulin sensitivity indexes obtained from oral
glucose tolerance testing: comparison with the euglycaemic insulin clamp.
Diabetes Care. 1999;22(9):1462–70.
11. Bonara E, Kiechl S, Willeit J, et al. Insulin resistance as estimated by
homeostasis model assessment predicts incident symptomatic
cardiovascular disease in Caucasian subjects from the general population:
the Bruneck study. Diabetes Care. 2007;30(2):318–24.
12. Pickup JC. Inflammation and activated innate immunity in the pathogensis
of type 2 diabetes. Diabetes Care. 2004;27(3):813–23.
13. Van Cromphaut S, Vanhorebeek I. D Berghe GV. Glucose metabolism and
insulin resistance in sepsis. Curr Pharm Des. 2008;14(19):1887–99.
14. Blumenthal A, Isovski F, Rhee KY. Tuberculosis and host metabolism: ancient
associations, fresh insights. Trans Res. 2009;154(1):7–14.
15. Bell L, Bhat V, George G, Awotedu AA, Gqaza B. Sluggish glucose tolerance
in tuberculosis patients. SAMJ. 2007;97(5):374–7.
16. Karachunskiĭ MA, Balabolkin MI, Beglarian NR. Changes in carbohydrate
metabolism in patients with tuberculosis. Vestn Ross Akad Med Nauk.
1995;7:18–21.
17. Hayashi S, Takeuchi M, Hatsuda K, et al. The impact of nutrition and glucose
intolerance on the development of tuberculosis in Japan. Int J Tuberc Lung
Dis. 2014;18(1):84–8.
18. Singh MM, Biswas SK, Ashok S, Ashok KR, Singh PP. Impaired glucose tolerance
in active pulmonary tuberculosis. Indian J Tuberc. 1984;31(3):118–21.
19. Jawad F, Shem AS, Memon R, Ansari G. Glucose intolerance in pulmonary
tuberculosis. J Pak Med Assoc. 1995;45(9):237–8.
20. Takasu N, Yamada T, Miura H, et al. Rifampicin-induced early phase
hyperglycemia in humans. Am Rev Respir Dis. 1982;125(1):23–7.
21. Stock KP, Riemann JF, Stadler W, Rösch W. Tuberculosis of the pancreas.
Endoscopy. 1981;13(4):178–80.
22. Broxmeyer L. Diabetes mellitus, tuberculosis and the mycobacteria: two
millennia of enigma. Med Hypotheses. 2005;65(3):433–9.
23. Erol A. Visceral adipose tissue specific persistence of mycobacterium
tuberculosis may be reason for the metabolic syndrome. Med Hypotheses.
2008;71(2):222–8.
24. Lee RD, Nieman DC. Nutritional Assessment. 3rd ed. New York: McGraw
Hill; 2003.
25. World Health Organization. BMI classification. http://apps.who.int/bmi/index.
jsp?introPage=intro_3.html. Accessed 25 May 2012.
26. World Health Organization. Waist circumference and waist: hip ratio.
Geneva: Report of a WHO Expert Consultation; 2008. p. 8–11.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of
low density lipoprotein cholesterol in plasma, without use of the
preparative ultracentrifuge. Clin Chem. 1972;18:499–501.
28. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R.
Homeostasis model assessment: insulin resistance and β-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia.
1985;28:412–9.
29. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check
index: a simple, accurate method for assessing insulin sensitivity in humans.
J Clin Endocrinol Metab. 2000;85(7):2402–10.
30. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin
resistance and carotid intima-media thickness and stenosis in non-diabetic
subjects. Results from a cross-sectional study in Malmo, Sweden. Diabetic
Med. 2000;17(4):299–307.
31. Marques-Vidal P, Mazoyer E, Bongard V, et al. Prevalence of insulin
resistance syndrome in southerwestern France and its relationship with
inflammatory and hemostatic markers. Diabetes Care. 2002;25(8):1371–7.
32. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing
insulin resistance by simple quantitative methods in subjects with normal
glucose metabolism. Diabetes Care. 2003;26(12):3320–5.
33. Lee S, Choi S, Kim HJ, et al. Cutoff values of surrogate measures of insulin
resistance for metabolic syndrome in Korean non-diabetic adults. J Korean
Med Sci. 2006;21(4):695–700.
34. Amod A, Ascott-Evans BH, Berg GI, et al. The 2012 SEMDSA guideline for
the Management of Type 2 diabetes. JEMDSA. 2012;17(1):1–94.
35. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide
definition. A consensus statement from the international diabetes
federation. Diabetic Med. 2006;23(5):469–80.
36. Expert Panel on Detection, Evaluation and Treatment. Executive summary of
the third report of the National Cholesterol Education Program (NCEP)
expert panel on detection, evaluation and treatment of high blood
cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–97.
37. Hood MLH. A narrative review of recent progress in understanding the
relationship between tuberculosis and protein energy malnutrition. Eur J
Clin Nutr. 2013;67:1122–8.
38. Edwards LB, Livesay VT, Acquaviva FA, Palmer CE. Height, weight, tuberculosis
infection, and tuberculous disease. Arch Environ Health. 1971;22(1):106–12.
39. Zachariah R, Spielmann MP, Harries AD, Salaniponi FM. Moderate to severe
malnutrition in patients with tuberculosis is a risk factor associated with
early death. Trans R Soc Trop Med Hyg. 2002;96(3):291–4.
40. Dodor EA. Evaluation of nutritional status of new tuberculosis patients at
the Effia Nkwanta regional hospital. Ghana Med J. 2008;42(1):22–8.
41. Villamor E, Saathoff E, Mugusi F, Bosch RJ, Urassa W, Fawzi WW. Wasting
and body composition of adults with pulmonary tuberculosis in relation
Philips et al. BMC Infectious Diseases  (2017) 17:570 Page 10 of 12
to HIV-1 coinfection, socioeconomic status and severity of tuberculosis.
Eur J Clin Nutr. 2006;60:163–71.
42. Directorate. TB DOTS Strategy Coordination, National Department of Health,
Pretoria, South Africa. Department of Health, Republic of South Africa.
National Tuberculosis Management Guidelines; 2014.
43. Schwenk A, Macallan D. Tuberculosis, malnutrition and wasting. Curr Opin
Clin Nutr Metab Care. 2000;3(4):285–91.
44. Paton NI, Ng YM. Body composition studies in patients with wasting
associated with tuberculosis. Nutrition. 2006;22(3):245–51.
45. PrayGod G, Range N, Faurholt-Jepsen D, et al. Weight, body composition
and handgrip strength among pulmonary tuberculosis patients: a matched
cross-sectional study in Mwanza, Tanzania. Trans R Soc Trop Med Hyg. 2011;
105(3):140–7.
46. Bhargava A, Chatterjee M, Jain Y, et al. Nutritional status of adult patients
with pulmonary tuberculosis in rural central India and its association with
mortality. PLoS One. 2013;8(10):e77979.
47. Frediani JK, Sanikidze E, Kipiani M, et al. Macronutrient intake and body
composition changes during anti-tuberculosis therapy in adults. Clin Nutr.
2015. http://dx.doi.org/10.1016/j.clnu.2015.02.007.
48. Kennedy N, Ramsay A, Uiso L, Gutmann J, Ngowi FI, Gillespie SH. Nutritional
status and weight gain in patients with pulmonary tuberculosis in Tanzania.
Trans R Soc Trop Med Hyg. 1996;90(2):162–6.
49. How SH, Kuan YC, Ng TH, Razali MR, Fauzi AR. Monitoring treatment
response in sputum smear positive pulmonary tuberculosis patients:
comparison of weight gain, sputum conversion and chest radiograph.
Malays J Pathol. 2014;36(2):91–6.
50. Opolot JO, Theron AJ, Anderson R, Feldman C. Acute phase proteins and
stress hormone responses in patients with newly diagnosed active
pulmonary tuberculosis. Lung. 2015;193(1):13–8.
51. Sahin F, Yildiz P. Distinctive biochemical changes in pulmonary tuberculosis
and pneumonia. Arch Med Sci. 2013;9(4):656.
52. Taha DA, Thanoon IAJ. Antioxidant status, C-reactive protein and iron
status in patients with pulmonary tuberculosis. SQU Medical Journal.
2010;10(3):361–9.
53. Peresi E, Silva SM, Calvi SA, Marcondes-Machado J. Cytokines and acute-
phase serum proteins as markers of inflammatory regression during
pulmonary tuberculosis treatment. J Bras Pneumol. 2008;34(11):942–9.
54. Bongiovanni B, Diaz A, D’Attilio L, et al. Changes in the immune and
endocrine responses of patients with pulmonary tuberculosis undergoing
specific treatment. Ann N Y Acad Sci. 2012;1262(1):10–5.
55. Gupta A, Shah A. Tuberculosis and diabetes: an appraisal. Ind J Tub. 2000;47(1):3–8.
56. Deniz O, Gumus S, Yaman H, et al. Serum total cholesterol, HDL-C and LDL-
C concentrations significantly correlate wtih radiological extent of disease
and the degree of smear positively in patients with pulmonary tuberculosis.
Clin Biochem. 2007;40(3):162–6.
57. Sammalkorpi K, Valtonen V, Kerttula Y, Nikkilä E, Taskinen MR. Changes
in serum lipoprotein pattern induced by acute infections. Metab.
1988;37(9):859–65.
58. Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the
concentration and density distribution of plasma lipids and apolipoporiteins.
J Lipid Res. 1989;30:39–49.
59. Deniz O, Tozkoprana E, Yaman H, et al. Serum HDL-C levels, log (TG/HDL-C)
values and serum total cholesterol/HDL-C ratios significantly correlate with
radiological extent of disease in patients with community acquired
pneumonia. Clin Biochem. 2006;39(3):287–92.
60. Tietge UJ, Maugeais C, Lund-Katz S, Grass D, de Beer FC, Rader DJ.
Human secretory phospholipase A2 mediates decreased plasma
concentrations of HDL-C cholesterol and Apoa-I in response to
inflammation in human Apoa-I transgenic mice. Arterioscler Thromb
Vasc Biol. 2002;22(7):1213–8.
61. Artl A, Marsche G, Lestavel S, Sattler W, Malle E. Role of serum amyloid a
during metabolism of acute-phase HDL-C by macrophages. Arterioscler
Thromb Vasc Biol. 2000;20(3):763–72.
62. Miida T, Yamada T, Yamadera T, Ozaki K, Inano K, Okada M. Serum amyloid
a protein generates Preβ1 high-density lipoprotein from alpha-migrating
high-density lipoprotein. Biochemist. 1999;38(51):16958–62.
63. Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum
amyloid a (SAA): influence on HDL-C-mediated cellular cholesterol efflux.
Lipid Res. 1999;36(5):1058–65.
64. De Moraes ML, de Paula RM, Delogo KN, et al. Association of serum levels
of iron, copper and zinc, and inflammatory markers with bacteriological
sputum conversion during tuberculosis treatment. Biol Trace Elem Res.
2014;160(2):176–84.
65. Lawn SD, Obeng J, Acheampong JW, Griffin GE. Resolution of the acute-
phase response in west African patients receiving treatment for pulmonary
tuberculosis. Int J Tuberc Lung Dis. 2000;4(4):340–4.
66. Jeon CY, Harries AD, Baker MA, et al. Bi-directional screening for
tuberculosis and diabetes: a systematic review. Tropical Med Int Health.
2010;15(11):1300–14.
67. Ade S, Affolabi D, Agodokpessi P, et al. Low prevalence of diabetes mellitus
in patients with tuberculosis in Cotonou. Benin PHA. 2015;5(2):147–9.
68. Rajapakshe W, Isaakidis P, Sagili KD, et al. Screening patiens with
tuberculosis for diabetes mellitus in Ampara. Sri Lanka PHA.
2015;5(2):150–2.
69. Oluboyo PO, Erasmus RT. The significance of glucose intolerance in
pulmonary tuberculosis. Tubercle. 1990;71(2):135–8.
70. Faurholt-Jepsen D, Range N, PrayGod G, et al. Diabetes is a risk factor for
pulmonary tuberculosis: A case-control study from Mwanza, Tanzania. PloS
ONE. 2011;6(8):1–5.(e24215).
71. Matsuda M. Measuring and estimating insulin resistance in clinical and
research settings. Nutr Metab Cardiovasc Dis. 2010;20(2):79–86.
72. Monzillo LA, Hamdy O. Evaluation of insulin sensitivity in clinical practice
and in research settings. Nutr Rev. 2003;61(12):397–412.
73. Kapur A, Harries AD. The double burden of diabetes and tuberculosis –
public health implications. Diabetes Res Clin Pract. 2013;101(1):10–9.
74. Başoğlu OK, Bacakoğlu F, Cok G, Sayiner A, Ateş M. The oral glucose
tolerance test in patients with respiratory infections. Monaldi Arch Chest
Dis. 1999;54(4):307–10.
75. Stevenson CR, Forouhi NG, Roglic G, et al. Diabetes and tuberculosis: the
impact of the diabetes epidemic on tuberculosis incidence. BMC Public
Health. 2007;7(1):234.
76. Viswanathan V, Kumpatla S, Aravindalochanan V, et al. Prevalence of
diabetes and pre-diabetes and associated risk factors among tuberculosis
patients in India. PLoS One. 2012;7(7):e41367.
77. Balakrishnan S, Vijayan S, Nair S, et al. High diabetes prevalence among
tuberculosis cases in Kerala. India PLoS One. 2012;7(10):e46502.
78. Restrepo BI, Fisher-Hoch SP, Smith B, et al. Mycobacterial clearance from
sputum is delayed during the first phase of treatment in patients with
diabetes. Am J Trop Med Hyg. 2008;79(4):541–4.
79. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for
quantifying insulin secretion and resistance. Am J Phys. 1979;237(3):214–23.
80. Ryan AS. Insulin resistance with aging. Sports Med. 2000;30(5):327–46.
81. Ford ES. Prevalence of the metabolic syndrome defined by the
international diabetes federation among adults in the US. Diabetes
Care. 2005;28(11):2745–9.
82. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome
responsible for NIDDM, obesity, hypertension, dyslipidemia, and
atherosclerotic vascular disease. Diabetes Care. 1991;14(3):173–94.
83. Knowles JW, Xie W, Zhang Z, et al. Identification and validation of
N-acetyltransferase 2 as an insulin sensitivity gene. J Clin Invest.
2015;125(4):1739–51.
84. Simarro RM, Carbayo HJ, Massó OJ, et al. Association of insulin resistance
with different anthropometric measures and cardiovascular risk factors in a
non-diabetic popualation. Endocrinol Nutr. 2011;58(9):464–71.
85. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship beween
several surrogate estimates of insulin resistance and quantification of
insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers.
Diabetes Care. 2000;23(2):171–5.
86. Esteghamati A, Khalilzadeh O, Anvari M, Ahadi MS, Abbasi M, Rashidi A.
Metabolic syndrome and insulin resistance significantly correlate with body
mass index. Arch Med Res. 2008;39(8):803–8.
87. Gayoso-Diz P, Otero-Gonzalez A, Rodriguez-Alvarez MX, et al. Insulin
resistance index (HOMA-IR) levels in a general adult population: curves
percentile by gender and age. The EPIRCE study. Diab Res Clin Pract.
2011;94(1):146–55.
88. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of
metabolic syndrome. Report of the National Heart, lung and blood
institute/American Heart Association conference on scientific issues related
to definition. Circulation. 2004;109(3):433–8.
89. Addo OY, Pereira MA, Himes JH. Is skinfold thickness as good as DXA when
measuring adipositiy contributions to insulin resistance in adolescents? Am
J Hum Bio. 2012;24(6):806–11.
Philips et al. BMC Infectious Diseases  (2017) 17:570 Page 11 of 12
90. Jellinger PS. Metabolic consequences of hyperglycemia and insulin resistance.
Insulin. 2009;4(1):2–14.
91. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in
healthy subjects: associations with obesity, insulin resistance, and
endothelial dysfunction. A potential role for cytokines originating from
adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972–8.
92. Fonseca V, Desouza C, Asnani S, Jialal I. Nontraditional risk factors for
cardiovascular disease in diabetes. Endocrinol Rev. 2004;25(1):153–75.
93. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin
modulates the T-cell immune response and reverses starvation-induced
immuno-suppression. Nature. 1998;394(6696):897–901.
94. Berglund E, Vianna C, Donato J, et al. Direct leptin action of POMC neurons
regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin
Invest. 2012;122:1000–9.
95. Zheng Y, Ma A, Wang Q, et al. Relation of leptin, ghrelin and inflammatory
cytokines with body mass index in pulmonary tuberculosis patients with
and without type 2 diabetes mellitus. PLoS One. 2013;8(11):e80122.
96. Yüksel I, Şencan M, Dökmetas HS, Dökmetas I, Ataseven H, Yönem O. The
relation between serum leptin levels and body fat mass in patients with
active lung tuberculosis. Endocr Res. 2003;29(3):257–64.
97. Çakir B, Yönem A, Güler S, et al. Relation of leptin and tumor necrosis factor
alpha to body weight changes in patients with pulmonary tuberculosis.
Horm Res. 1999;52(6):279–83.
98. Van Crevel R, Ottenhoff THM, van der Meer JWM. Innate immunity to
Mycobacterium tuberculosis. Clin Microbiol Rev. 2002;15(2):294–309.
99. Van Lettow M, van der Meer JWM, West CE, van Crevel R, Semba RD.
Interleukin-6 and human immunodeficiency virus load, but not plasma
leptin concentration, predict anorexia and wasting in adults with pulmonary
tuberculosis in Malawi. J Clin Endocrinol Metab. 2005;90(8):4771–6.
100. Schwenk A, Hodgson I, Rayner CF, Griffin GE, Macallan DC. Leptin
and energy metabolism in pulmonary tuberculosis. Am J Clin Nutr.
2003;77(2):392–8.
101. Keicho N, Matsushita I, Tanaka T, et al. Circulating levels of adiponectin,
leptin, fetuin-a and retinol-binding protein in patients with tuberculosis:
markers of metabolism and inflammation. PLoS One. 2012;7(6):e38703.
102. Ravussin E, Pratley R, Maffei M, et al. Relatively llow plasma leptin
concentrations precede weight gain in pima Indians. Nat Med.
1997;3:238–40.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Philips et al. BMC Infectious Diseases  (2017) 17:570 Page 12 of 12
